A carregar...
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
BACKGROUND: Brodalumab is a fully human anti–interleukin-17 receptor A monoclonal antibody efficacious for the treatment of adults with moderate-to-severe plaque psoriasis. OBJECTIVE: This study summarizes malignancy rates in psoriasis clinical studies of brodalumab. METHODS: Data were pooled from o...
Na minha lista:
| Publicado no: | Am J Clin Dermatol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7275023/ https://ncbi.nlm.nih.gov/pubmed/32207067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40257-020-00512-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|